7 Analysts Have This to Say About CymaBay Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 7 analysts have published their opinion on CymaBay Therapeutics (NASDAQ:CBAY) stock. The majority of these analysts are bullish, with 5 giving a bullish rating and 2 somewhat bullish. The average 12-month price target for the stock is $14.86, which has increased by 14.31% over the past month.
July 31, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CymaBay Therapeutics (NASDAQ:CBAY) has received positive ratings from 7 analysts over the past 3 months. The average 12-month price target for the stock is $14.86, indicating a potential upside.
The bullish ratings and increased price target from analysts indicate a positive outlook for CymaBay Therapeutics. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100